Many efforts have been made in the worldwide quest for a prophylactic HIV vaccine to end the AIDS
pandemic, but none has yet succeeded. The lessons learned have repeatedly informed us that the traditional or
conventional approaches directly using the pathogens or subunits will not be sufficient for an effective HIV/AIDS
vaccine. Recent advances in structure-based technology have shown some promise in the quest for a better immunogen in
HIV vaccine development. According to the basic binding structural relationship of an antigen and an antibody, structurebased
antigen design could bring some hope for the development of an effective vaccine against HIV.
Keywords: Antibody epitope, envelope trimer, germline B-cells, HIV-1, immunogen design, structure-based design, vaccine
Rights & PermissionsPrintExport